Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Advanced Weight Loss Stack

Peptide Schedule Research Team

+

Dual GIP/GLP-1 agonist for maximum appetite suppression combined with HGH fragment for targeted fat metabolism. Tirzepatide acts on both GIP and GLP-1 receptors for superior weight loss compared to single-agonist peptides, while AOD-9604 enhances lipolysis without affecting blood sugar or growth.

20.2% body weight gone at 72 weeks, and that was the average, not the ceiling. Tirzepatide (LY3298176, CAS 2023788-19-2) is a 39-amino acid acylated lipopeptide sold as Zepbound for obesity and Mounjaro for type 2 diabetes. It activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously.

The dual receptor mechanism separates tirzepatide from single-target GLP-1 drugs like semaglutide. GIP receptor activation improves fat metabolism and may reduce the nausea burden that limits GLP-1-only treatment. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and boosts insulin secretion. Those two pathways working together produce weight loss and glycemic control that neither achieves alone.

SURMOUNT-1 (PMID 35658024, n=2,539) showed dose-dependent results at 72 weeks. Its treatment-regimen estimand counts everyone randomized, including people who stopped the drug. On that basis, mean weight loss was 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% on placebo. SURMOUNT-5 (PMID 40353578, n=751) ran a direct comparison; tirzepatide reached 20.2% versus semaglutide's 13.7%. Roughly one in five tirzepatide patients lost 30% or more of their body weight.

The r/Zepbound community (180,000+ members) confirms what the trials found. Appetite suppression starts within days. Most users stabilize at 7.5 to 12.5 mg rather than pushing to the maximum 15 mg dose. Cost and insurance coverage remain the biggest barriers. Weight regain after stopping is well-documented; about two-thirds of lost weight returns within a year of discontinuation.

LevelDose / InjectionFrequency
Beginner2.5 mgWeekly
Moderate5 mgWeekly
Aggressive15 mgWeekly

About 2.6 kg of weight loss over 12 weeks on 1 mg a day by mouth, versus about 0.8 kg on placebo. That was the best arm of a 12-week trial of the AOD-9604 peptide (also called hGH fragment 177-191 or hGH frag, CAS 221231-10-3) in 300 obese adults. It was published only as a 2005 meeting abstract (Herd et al., Obesity Research). FDA's December 2024 PCAC briefing gives the rates: 0.22 kg a week versus 0.07 kg on placebo. Then the larger Phase IIb trial with 536 subjects ran for 24 weeks, added strict diet and exercise controls, and missed its primary endpoint. Metabolic Pharmaceuticals terminated the program in 2007.

How AOD-9604 works is still unsettled. Unlike full-length growth hormone, it does not bind the GH receptor (PMID 11673763). Blood sugar stays flat. IGF-1 stays flat. Beta-3 adrenergic receptors seem to matter, but AOD-9604 has not been shown to activate them (details under How AOD-9604 Works). FDA's 2024 briefing says the molecular target is still unknown.

Community use looks different from the clinical program. Most users inject 300 to 500 mcg subcutaneously each morning on an empty stomach. Users usually justify that range by converting the 1 mg oral clinical dose with an assumed 40% oral bioavailability. FDA's 2024 briefing calls oral bioavailability unclear even in animals, and no human SC pharmacokinetic study exists. Across 50 to 150 Reddit threads in r/Peptides, the consensus is consistent: AOD-9604 is a mild add-on, not a primary fat loss tool. It performs best when stacked with CJC-1295 and Ipamorelin in a caloric deficit. Anyone expecting GLP-1-level results will be disappointed.

LevelDose / InjectionFrequency
Beginner200 mcgDaily
Moderate300 mcgDaily
Aggressive500 mcgDaily

Interactions

Tirzepatide + AOD-9604Synergistic

Advanced weight loss stack. Tirzepatide provides dual GIP/GLP-1 suppression while AOD-9604 adds targeted fat metabolism.

Check these 2 in the interaction checker

Protocol Tips

  • Tirzepatide requires slow titration — follow the GLP-1 titration protocol.
  • AOD-9604 is best dosed fasted, ideally first thing in the morning.
  • Nausea is common early on with Tirzepatide; it typically resolves within 1-2 weeks.
  • Prioritize high-protein meals to preserve lean mass during weight loss.

Related Guides & Comparisons

Beginner-tier doses from each peptide's page load into a preview you can change.

Explore all Weight Loss peptides